Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effectsfor Malignancy626 locations incl. AnchorageSponsor: Alliance for Clinical Trials in OncologySex: All·Age: All agesCode: NCT04242095·RecruitingApply to this trial
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myelomafor Smoldering Plasma Cell MyelomaDrug: Daratumumab741 locations incl. BirminghamSponsor: ECOG-ACRIN Cancer Research GroupSex: All·Age: 18+Code: NCT03937635·Phase 3·RecruitingApply to this trial
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumorsfor Bladder AdenocarcinomaDrug: Cabozantinib578 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT03866382·Phase 2·RecruitingApply to this trial
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancerfor Previously Treated Non-Small Cell Lung Cancer1229 locations incl. BirminghamSponsor: SWOG Cancer Research NetworkSex: All·Age: 18+Code: NCT03851445·Phase 2, Phase 3·RecruitingApply to this trial
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Changefor Advanced Lung Non-Small Cell CarcinomaDrug: Osimertinib345 locations incl. AnchorageSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT03191149·Phase 2·RecruitingApply to this trial
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgeryfor Head and Neck Squamous Cell Carcinoma676 locations incl. BirminghamSponsor: ECOG-ACRIN Cancer Research GroupSex: All·Age: 18+Code: NCT02734537·Phase 2·RecruitingApply to this trial
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomasfor Intracranial Meningioma780 locations incl. BirminghamSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT02523014·Phase 2·RecruitingApply to this trial